Synthesis and structure based optimization of novel Akt inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 11, 2008, Pages 3359-3363

  Lippa, Blaise ^a   Pan, Gonghua ^a   Corbett, Matthew ^a   Li, Chao ^a   Kauffman, Goss S ^a   Pandit, Jayvardhan ^a   Robinson, Shaughnessy ^a   Wei, Liuqing ^a   Kozina, Ekaterina ^a   Marr, Eric S ^a   Borzillo, Gary ^a   Knauth, Elisabeth ^a   Barbacci Tobin, Elsa G ^a   Vincent, Patrick ^a   Troutman, Merin ^a   Baker, Deborah ^a   Rajamohan, Francis ^a   Kakar, Shefali ^a   Clark, Tracey ^a   Morris, Joel ^a  

^a PFIZER INC   (United States)

Author keywords

Akt; Imidazopiperidine; Pyrrolopyrimidine; Spiroindoline

Indexed keywords

PROTEIN KINASE B INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; MOUSE; NONHUMAN; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DRUG DESIGN; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44149113025     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.034     Document Type: Article

References (28)

1. Bellacosa A., Franke T.F., and Gonzalez-Portal M.E. Oncogene 8 (1993) 745
2. Fayard E., Tintignac L., Baudry A., and Hemmings B. J. Cell Sci. 24 (2005) 7455
3. Altomare D.A., and Testa J.R. Oncogene 24 (2005) 7455
4. Borzillo G.V. Drug Discov. Today: Ther. Strateg. 2 (2005) 331
5. LoPiccolo J., Granville C.A., Gills J.J., and Dennis P.A. Anti-Cancer Drugs 18 (2007) 861
6. Samuels Y., and Ericson K. Curr. Opin. Oncol. 18 (2006) 77
7. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage1 S., Uhlik M., Lin A., Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., and Thomas J.E. Nature 448 (2007) 439
8. Pedrero J.M.G., Carracedo D.G., Pinto C.M., Zapatero A.H., Rodrigo J.P., Nieto C.S., and Gonzalez M.V. Int. J. Cancer 114 (2005) 242
9. Li Q. Expert Opin. Ther. Patents 17 (2007) 1077
10. Lindsley C.W., Barnett S.F., Yaroschak M., Bilodeau M.T., and Layton M.E. Curr. Topics Med. Chem. 7 (2007) 1349
11. Lindsley C.W., Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huberb H.E., and Duggan M.E. Bioorg. Med. Chem. Lett. 15 (2005) 761
12. Kozikowski A.P., Sun H., Brognard J., and Dennis P.A. J. Am. Chem. Soc. 125 (2003) 1144
13. Zhu G.-D., Gandhi V.B., Gong J., Thomas S., Woods K.W., Song X., Li T., Diebold R.B., Luo Y., Liu X., Guan R., Klinghofer V., Johnson E.F., Bouska J., Olsen A., Marsh K.C., Stoll V.S., Mamo M., Polakowski J., Campbell T.J., Martin R.L., Gintant G.A., Penning T.D., Li Q., Rosenberg S.H., and Giranda V.L. J. Med. Chem. 50 (2007) 2990
14. Luo Y., Shoemaker A.R., Liu X., Woods K.W., Thomas S.A., De Jong R., Han E.K., Li T., Stoll V.S., Powlas J.A., Oleksijew A., Mitten M.J., Shi Y., Guan R., McGonigal T.P., Klinghofer V., Johnson E.F., Leverson J.D., Bouska J.J., Mamo M., Smith R.A., Gramling-Evans E.E., Zinker B.A., Mika A.K., Nguyen P.T., Oltersdorf T., Rosenberg S.H., Li Q., and Giranda V.L. Mol. Cancer Ther. 4 (2005) 977
15. Lin X., Murray J.M., Rico A.C., Wang M.X., Chu D.T., Zhou Y., Del Rosario M., Kaufman S., Ma S., Fang E., Crawford K., and Jefferson A.B. Bioorg. Med. Chem. Lett. 16 (2006) 4163
16. Breitenlechner C.B., Wegge T., Berillon L., Graul K., Marzenell K., Friebe W.-G., Thomas U., Schumacher R., Huber R., Engh R.A., and Masjost B. J. Med. Chem. 48 (2005) 163
17. Lippa B. Expert Opin. Ther. Patents 17 (2007) 577
18. Donald A., McHardy T., Rowlands M.G., Hunter L.-J.K., Davies T.G., Berdini V., Boyle R.G., Aherne W., Garrett M.D., and Collins I. J. Med. Chem. 50 (2007) 2289
19. Saxty G., Woodhead S.J., Berdini V., Davies T.G., Verdonk M.L., Wyatt P.G., Boyle R.G., Barford D., Downham R., Garrett M.D., and Carr R.A. J. Med. Chem. 50 (2007) 2293
20. 50 of 223 ± 110 nM. As expected, no compounds tested have shown Akt isozyme selectivity (Akt1, 2 or 3).
21. Potts K.T., and Brugel E.G. J. Org. Chem. 35 (1970) 3448
22. Gerster J.F., Hinshaw B.C., Robins R.K., and Townsend L.B. J. Heterocycl. Chem. 6 (1969) 207
23. Pandit, J. WO 2005113762A1, 2005; Atomic coordinates and structure factors of the protein structures in this paper have been deposited in the RCSB Protein Data Bank, with accession numbers 3CQU and 3CQW.
24. Habermehl G.G., and Ecsy W. Heterocycles 5 (1976) 127
25. Maligres P.E., Houpis I., Rossen K., Molina A., Sager J., Upadhyay V., Wells K.M., Reamer R.A., Lynch J.E., Askin D., Volante R.P., Reider P.J., and Houghton P. Tetrahedron 53 (1997) 10983
26. Akt cell assay: The phosphorylation status of an Akt substrate, GSK-3α, in the U87 glioblastoma line is measured. Cells were incubated with compound (7 concentrations plus vehicle) for 2 h in DMEM medium lacking fetal calf serum (FCS). After cell lysis, p-GSK-3α was captured on 96-well plates coated with a phosphospecific antibody to GSK-3α/β (#9331, Cell Signaling Technology). The reporter antibody bound total GSK-3α (#SC-5264, Santa Cruz), and was measured in an ELISA format.
27. Unfortunately, it was not possible to obtain high-quality crystal structures on any member of the spiroindoline lead series (13).
28. Hopkins A.L., Groom C.R., and Alex A. Drug Discov. Today 9 (2004) 430